Aldagen, Inc. – Product Pipeline Review – Q1 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 44

More Info
									      Aldagen, Inc. – Product Pipeline Review – Q1 2011
                                                                                          Reference Code: GMDHC0988CDB

                                                                                                Publication Date: MAR 2011




Aldagen, Inc. – Product Pipeline Review – Q1 2011                                           GMDHC0988CDB / Published MAR 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Aldagen, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Aldagen, Inc. Snapshot                                                                                                5
    Aldagen, Inc. Overview                                                                                            5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Aldagen, Inc. – Research and Development Overview                                                                     6
    Key Therapeutic Areas                                                                                             6
Aldagen, Inc. – Pipeline Review                                                                                       8
    Pipeline Products by Stage of Development                                                                         8
    Pipeline Products – Monotherapy                                                                                   9
Aldagen, Inc. – Pipeline Products Glance                                                                             10
    Aldagen, Inc. – Late Stage Pipeline                                                                              10
         Phase III Products/Combination Treatment Modalities                                                         10
    Aldagen, Inc. Clinical Stage Pipeline Products                                                                   11
         Phase II Products/Combination Treatment Modalities                                                          11
         Phase I Products/Combination Treatment Modalities                                                           12
Aldagen, Inc. – Drug Profiles                                                                                        13
    ALD-101                                                                                                          13
         Product Description                                                                                         13
         Mechanism of Action                                                                                         13
         R&D Progress                                                                                                13
    ALD-301                                                                                                          15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    ALD-401                                                                                                          16
         Product Description                                                                                         16
         Mechanism of Action                                                                                         16
         R&D Progress                                                                                                16
    ALD-151                                                                                                          17
         Product Description                                                                                         17
         R&D Progress                                                                                                17
    ALD-201                                                                                                          18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    ALD-601                                                                                                          19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    ALDHbr Umbilical Cord Blood cells                                                                                20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20




Aldagen, Inc. – Product Pipeline Review – Q1 2011                                         GMDHC0988CDB / Published MAR 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Aldagen, Inc. – Product Pipeline Review



Aldagen, Inc. – Pipeline Analysis                                                                                                             21
    Aldagen, Inc. – Pipeline Products by Therapeutic Class                                                                                    21
    Aldagen, Inc. - Pipeline Products By Target                                                                                               22
    Aldagen, Inc. – Pipeline Products by Route of Administration                                                                              23
    Aldagen, Inc. – Pipeline Products by Molecule Type                                                                                        24
Aldagen, Inc. – Recent Pipeline Updates                                                                                                       25
Aldagen, Inc. – Locations And Subsidiaries                                                                                                    26
    Head Office                                                                                                                               26
Recent Developments                                                                                                                           27
         Aug 05, 2009: Aldagen Reaches Agreement With FDA On A Special Protocol Assessment (SPA) For Phase 3 Trial Of ALD-301 For
         Critical Limb Ischemia                                                                                                               27
         Oct 29, 2008: Aldagen Receives Orphan Drug Designation For ALD-101                                                                   27
         Apr 16, 2008: Aldagen Announces Initiation Of ALD-101 Phase III Trial For Improving Cord Blood Transplants In Pediatric Patients With
         Inherited Metabolic Diseases                                                                                                          28
Financial Deals Landscape                                                                                                                     29
    Aldagen, Inc., Deals Volume Summary, 2004 to YTD 2011                                                                                     29
    Aldagen, Inc., Deals Summary By Region, 2004 to YTD 2011                                                                                  30
    Aldagen, Inc., Deals Summary, 2004 to YTD 2011                                                                                            31
    Aldagen, Inc. Detailed Deal Summary                                                                                                       32
         Venture Financing                                                                                                                    32
         Aldagen Secures $7.3 Million In Debt Financing                                                                                       32
         Aldagen Secures $18.4 Million In Fourth Round Of Financing                                                                           33
         Aldagen Secures Additional $9 Million In Series C Round Of Financing                                                                 35
         Aldagen Secures $14.3 Million In Series C Round Of Financing                                                                         37
         Equity Offering                                                                                                                      39
         Aldagen Files Registration Statement For Initial Public Offering Of $80.5 Million                                                    39
         Aldagen Enters Into Agreement With StemCell Technologies                                                                             41
         Aldagen Enters Into Co-Development Agreement With Innovative Micro Technology                                                        42
Appendix                                                                                                                     
								
To top